Your browser doesn't support javascript.
loading
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers.
Fultang, Livingstone; Panetti, Silvia; Ng, Margaret; Collins, Paul; Graef, Suzanne; Rizkalla, Nagy; Booth, Sarah; Lenton, Richard; Noyvert, Boris; Shannon-Lowe, Claire; Middleton, Gary; Mussai, Francis; De Santo, Carmela.
  • Fultang L; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Panetti S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Ng M; Department of Anatomic Pathology, The Chinese University of Hong Kong, Hong Kong.
  • Collins P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Graef S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Rizkalla N; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Booth S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Lenton R; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Noyvert B; CRUK Birmingham Centre and Centre for Computational Biology, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Shannon-Lowe C; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Middleton G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Mussai F; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. Electronic address: francis.mussai@nhs.net.
  • De Santo C; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
EBioMedicine ; 47: 235-246, 2019 Sep.
Article en En | MEDLINE | ID: mdl-31462392
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T / Células Supresoras de Origen Mieloide / Antineoplásicos Inmunológicos / Gemtuzumab / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T / Células Supresoras de Origen Mieloide / Antineoplásicos Inmunológicos / Gemtuzumab / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2019 Tipo del documento: Article